<SEC-DOCUMENT>0001213900-25-096128.txt : 20251003
<SEC-HEADER>0001213900-25-096128.hdr.sgml : 20251003
<ACCEPTANCE-DATETIME>20251003163036
ACCESSION NUMBER:		0001213900-25-096128
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251003
DATE AS OF CHANGE:		20251003

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SAB Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001833214
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				853899721
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92283
		FILM NUMBER:		251374388

	BUSINESS ADDRESS:	
		STREET 1:		777 W 41ST ST
		STREET 2:		SUITE 401
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33140
		BUSINESS PHONE:		305-845-2813

	MAIL ADDRESS:	
		STREET 1:		777 W 41ST ST
		STREET 2:		SUITE 401
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33140

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Big Cypress Acquisition Corp.
		DATE OF NAME CHANGE:	20201120

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vivo Opportunity Fund Holdings, L.P.
		CENTRAL INDEX KEY:			0001930214
		ORGANIZATION NAME:           	
		EIN:				873802421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		192 LYTTON AVENUE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
		BUSINESS PHONE:		6506880818

	MAIL ADDRESS:	
		STREET 1:		192 LYTTON AVENUE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Vivo Opportunity Fund Holdings, L.P. -->
          <cik>0001930214</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/29/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001833214</issuerCik>
        <issuerName>SAB Biotherapeutics, Inc.</issuerName>
        <issuerCusip>78397T202</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>777 W 41st St, Suite 401</com:street1>
          <com:city>Miami Beach</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33140</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Vivo Opportunity Fund Holdings, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>25931000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>25931000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>25931000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>(1) The reported share amount represents an aggregate of (i) 4,000,000 shares of common stock, par value $0.0001 per share (the "Common Stock") of SAB Biotherapeutics, Inc. (the "Issuer"), which were converted automatically from 40,000 shares of the Issuer's Series B Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock") on September 29, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 6,372,400 shares of Common Stock issuable upon conversion of 63,724 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement.  All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(2) The Series B Preferred Stock, the Enrollment Warrant and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Vivo Opportunity, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>25931000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>25931000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>25931000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>(1) The reported share amount represents an aggregate of (i) 4,000,000 shares of Common Stock of the Issuer, which were converted automatically from 40,000 shares of the Issuer's Series B Preferred Stock on September 29, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 6,372,400 shares of Common Stock issuable upon conversion of 63,724 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement.  All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(2) The Series B Preferred Stock, the Enrollment Warrant and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Vivo Opportunity Cayman Fund, L.P.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2619000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2619000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2619000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>(1) The reported share amount represents an aggregate of (i) 401,500 shares of Common Stock of the Issuer, which were converted automatically from 4,015 shares of the Issuer's Series B Preferred Stock on September 29 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 646,100 shares of Common Stock issuable upon conversion of 6,461 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement.  All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(2) The Series B Preferred Stock, the Enrollment Warrant and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Vivo Opportunity Cayman, LLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2619000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2619000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2619000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>(1) The reported share amount represents an aggregate of (i) 401,500 shares of Common Stock of the Issuer, which were converted automatically from 4,015 shares of the Issuer's Series B Preferred Stock on September 29, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 646,100 shares of Common Stock issuable upon conversion of 6,461 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement.  All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(2) The Series B Preferred Stock, the Enrollment Warrant and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>SAB Biotherapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>777 W 41st St, Suite 401, Miami Beach, Florida, 33140</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>192 Lytton Avenue, Palo Alto, CA 94301</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.

Vivo Opportunity, LLC is a Delaware limited liability company.

Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership.

Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Vivo Opportunity, LLC may be deemed to beneficially own an aggregate of 25,931,000 shares of the Issuer's securities, consisting of (i) 4,000,000 shares of Common Stock of the Issuer, which were converted automatically from 40,000 shares of the Issuer's Series B Preferred Stock on September 29, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 6,372,400 shares of Common Stock issuable upon conversion of 63,724 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

Vivo Opportunity Cayman, LLC may be deemed to beneficially own an aggregate of 2,619,000 shares of the Issuer's securities, consisting of (i) 401,500 shares of Common Stock of the Issuer, which were converted automatically from 4,015 shares of the Issuer's Series B Preferred Stock on September 29, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 646,100 shares of Common Stock issuable upon conversion of 6,461 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrant that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement.  These securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.

The Series B Preferred Stock, the Enrollment Warrant and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.</amountBeneficiallyOwned>
        <classPercent>Vivo Opportunity Fund Holdings, L.P.:       9.99%
Vivo Opportunity, LLC:                            9.99%
Vivo Opportunity Cayman Fund, L.P.:       9.99%
Vivo Opportunity Cayman, LLC:               9.99%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Vivo Opportunity Fund Holdings, L.P.:       25,931,000 shares
Vivo Opportunity, LLC:                              25,931,000 shares
Vivo Opportunity Cayman Fund, L.P.:      2,619,000 shares
Vivo Opportunity Cayman, LLC:           2,619,000 shares</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Vivo Opportunity Fund Holdings, L.P.: 25,931,000 shares
Vivo Opportunity, LLC:                        25,931,000 shares
Vivo Opportunity Cayman Fund, L.P.: 2,619,000 shares
Vivo Opportunity Cayman, LLC:         2,619,000 shares</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>99.1   Joint Filing Statement</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Vivo Opportunity Fund Holdings, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Kevin Dai</signature>
        <title>Kevin Dai/Managing Member of General Partner</title>
        <date>10/03/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Vivo Opportunity, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Kevin Dai</signature>
        <title>Kevin Dai/Managing Member</title>
        <date>10/03/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Vivo Opportunity Cayman Fund, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Kevin Dai</signature>
        <title>Kevin Dai/Managing Member of General Partner</title>
        <date>10/03/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Vivo Opportunity Cayman, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Kevin Dai</signature>
        <title>Kevin Dai/Managing Member</title>
        <date>10/03/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026016801ex99-1_sab.htm
<DESCRIPTION>JOINT FILING STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joint Filing Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned acknowledge and agree that the foregoing statement
on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall
be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge
that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning
him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other
entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Date: October 3, 2025</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Vivo Opportunity Fund Holdings, L.P.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD>Vivo Opportunity, LLC, its General Partner</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Managing Member</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Vivo Opportunity, LLC</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Managing Member</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Vivo Opportunity Cayman Fund, L.P.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD COLSPAN="2">Vivo Opportunity Cayman, LLC, its General Partner</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Kevin Dai</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Managing Member</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Vivo Opportunity Cayman, LLC</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Kevin Dai</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Kevin Dai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Managing Member</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
